| World report on hearing World Health Organization World Health Organization, 2021 | 785 | 2021 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 477 | 2021 |
| Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors AJ Gallan, E Alexander, P Reid, F Kutuby, A Chang, KJ Henriksen American Journal of Kidney Diseases 74 (6), 853-856, 2019 | 71 | 2019 |
| WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of IL-6 antagonists and mortality among patients hospitalized for … M Shankar-Hari, CL Vale, PJ Godolphin, D Fisher, JPT Higgins, F Spiga, ... jama 326 (6), 499-518, 2021 | 67 | 2021 |
| COVIDOSE: a phase II clinical trial of low‐dose tocilizumab in the treatment of noncritical COVID‐19 pneumonia GW Strohbehn, BL Heiss, SJ Rouhani, JA Trujillo, J Yu, AJ Kacew, ... Clinical Pharmacology & Therapeutics 109 (3), 688-696, 2021 | 53 | 2021 |
| Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases JS Hausmann, K Kennedy, JF Simard, JW Liew, JA Sparks, TT Moni, ... The Lancet Rheumatology 3 (10), e707-e714, 2021 | 44 | 2021 |
| Management of immunotherapy-related toxicities in patients treated with immune checkpoint inhibitor therapy PD Reid, AS Cifu, AR Bass Jama 325 (5), 482-483, 2021 | 41 | 2021 |
| Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis AR Bass, N Abdel-Wahab, PD Reid, JA Sparks, C Calabrese, ... Annals of the rheumatic diseases 82 (7), 920-926, 2023 | 28 | 2023 |
| COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19 GW Strohbehn, BL Heiss, SJ Rouhani, JA Trujillo, J Yu, AJ Kacew, ... medRxiv, 2020.07. 20.20157503, 2020 | 25 | 2020 |
| Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation I Amigues, AH Pearlman, A Patel, P Reid, PC Robinson, R Sinha, ... Expert review of clinical immunology 16 (12), 1185-1204, 2020 | 24 | 2020 |
| Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study P Reid, DFL Liew, R Akruwala, AR Bass, KK Chan Journal for immunotherapy of cancer 9 (9), 2021 | 17 | 2021 |
| Immune checkpoint inhibitor–associated myositis: a distinct form of inflammatory myopathy D Saygin, N Ghosh, P Reid JCR: Journal of Clinical Rheumatology 28 (7), 367-373, 2022 | 14 | 2022 |
| Approach to patients with suspected rheumatic disease I Ventura, P Reid, R Jan Primary Care: Clinics in Office Practice 45 (2), 169-180, 2018 | 14 | 2018 |
| Applied clinical pharmacology in a crisis: Interleukin‐6 axis blockade and COVID‐19 GW Strohbehn, PD Reid, MJ Ratain Clinical Pharmacology & Therapeutics 108 (3), 425-427, 2020 | 12 | 2020 |
| Treatment of rheumatic adverse events of cancer immunotherapy P Reid, LC Cappelli Best Practice & Research Clinical Rheumatology 36 (4), 101805, 2022 | 11 | 2022 |
| Socially optimal pandemic drug dosing GW Strohbehn, WF Parker, PD Reid, WF Gellad The Lancet Global Health 9 (8), e1049-e1050, 2021 | 11 | 2021 |
| Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations KC Kurnit, P Reid, JW Moroney, GF Fleming Gynecologic Oncology 158 (3), 531-537, 2020 | 11 | 2020 |
| Facial palsy induced by checkpoint blockade: a single center retrospective study C Yuen, P Reid, Z Zhang, B Soliven, JJ Luke, K Rezania Journal of Immunotherapy 42 (3), 94-96, 2019 | 10 | 2019 |
| Association between rheumatic autoantibodies and immune-related adverse events K Mathias, S Rouhani, D Olson, AR Bass, TF Gajewski, P Reid The Oncologist 28 (5), 440-448, 2023 | 9 | 2023 |
| Checkpoint inhibitor-associated scleroderma and scleroderma mimics M Macklin, S Yadav, R Jan, P Reid Pharmaceuticals 16 (2), 259, 2023 | 8 | 2023 |
